NCT04585750 2026-03-12The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PMV Pharmaceuticals, IncPhase 1/2 Recruiting300 enrolled
NCT06109779 2026-03-04Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)AstraZenecaPhase 3 Active not recruiting757 enrolled
NCT04430738 2026-02-24Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersSeagen Inc.Phase 2 Active not recruiting40 enrolled 67 charts
NCT06282575 2026-02-24Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerJazz PharmaceuticalsPhase 3 Recruiting286 enrolled
NCT04426669 2026-02-23A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic EngineeringIntima Bioscience, Inc.Phase 1/2 Completed23 enrolled
NCT07023731 2026-02-19A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationArvinas Inc.Phase 1/2 Recruiting159 enrolled
NCT05194072 2026-01-09A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsSeagen Inc.Phase 1 Terminated250 enrolled